There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA. The ...
InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ...
Inflammatory Bowel Disease : Review in-depth clinical information, latest medical news, and guidelines on chronic inflammatory bowel disease symptoms, or IBD symptoms. Access information on ...
Division of Microbiology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, USA ...